Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16619995 | 0.81 | LOXL2 (0.36) | BRD4HRH3SMN1; SMN2PBRM1L3MBTL1 | |
| SCHEMBL16619441 | 0.78 | HRH3 (0.33) | BRD4HRH3CCNCCDK8 | |
| SCHEMBL1695177 | 0.75 | SMN1; SMN2 (0.41) | BRD4HRH3SMN1; SMN2PBRM1L3MBTL1 | |
| SCHEMBL17232696 | 0.73 | NQO1 (0.43) | TDP1SMN1; SMN2AKT1AKT2MAPK14 | |
| SCHEMBL20160365 | 0.72 | SMN1; SMN2 (0.35) | BRD4HRH3SMN1; SMN2PBRM1L3MBTL1 | |
| SCHEMBL12510331 | 0.72 | CCNC (0.45) | BRD4SMN1; SMN2PBRM1L3MBTL1CCNC | |
| SCHEMBL12510429 | 0.72 | SCN5A (0.42) | MAPK14 | |
| SCHEMBL254009 | 0.72 | GAA (0.44) | HRH3SMN1; SMN2PBRM1L3MBTL1MAPK14 | |
| SCHEMBL16686865 | 0.72 | PIM1 (0.38) | BRD4HRH3SMN1; SMN2PBRM1L3MBTL1 | |
| SCHEMBL12811142 | 0.72 | MCHR1 (0.40) | SMN1; SMN2AKT1AKT2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312585-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2013083206-A1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312585-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HRH4, HRH3, HRH2 | BRD4 57/4885APOBEC3G 2725/4885TDP1 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.